Literature DB >> 8841022

Excess risk of primary liver cancer in patients with diabetes mellitus.

H O Adami1, W H Chow, O Nyrén, C Berne, M S Linet, A Ekbom, A Wolk, J K McLaughlin, J F Fraumeni.   

Abstract

BACKGROUND: Chronic infection with hepatitis B virus, alcohol consumption, and cirrhosis of the liver are recognized risk factors for primary liver cancer. A few, but not all, studies have suggested that diabetes mellitus also increases risk for this cancer.
PURPOSE: We conducted a population-based cohort study to analyze the risk of developing primary liver cancer and biliary tract (gallbladder, extrahepatic bile ducts, and ampulla of Vater) cancers among patients with diabetes.
METHODS: A cohort of 153 852 patients with a hospital discharge diagnosis of diabetes in the period from 1965 through 1983 was identified by use of the Swedish In-patient Register. Follow-up for these patients extended from the date of cohort entry through December 31, 1989. Incident cases of cancer during follow-up were identified through the Swedish Cancer Registry. To minimize the impact of selection bias, we excluded from the analysis patients who were diagnosed with liver and biliary tract cancers during the first year of follow-up. Standardized incidence ratios (SIRs) and their 95% confidence intervals (CIs) were computed by use of nationwide rates of liver and biliary tract cancers, adjusted for age, sex, and calendar year, for comparison.
RESULTS: During 1-24 years of follow-up, 819 incident cancers in the combined category of primary liver (n = 533) and biliary tract (n = 286) were identified in the cohort, yielding an overall SIR of 2.5 (95% CI = 2.3-2.6). The risk was higher in men (SIR = 3.2; 95% CI = 2.9-3.6) than in women (SIR = 2.0; 95% CI = 1.8-2.2). The incidence of primary liver cancer alone was increased fourfold (SIR = 4.1; 95% CI = 3.8-4.5); again, the risk was higher in men (SIR = 4.7; 95% CI = 4.2-5.2) than in women (SIR = 3.4; 95% CI = 2.9-3.9). Smaller increases in risk were seen for cancers of the gallbladder, the extrahepatic bile ducts, and the ampulla of Vater. After exclusion of diabetic patients with concomitant diseases that predispose to primary liver cancer, such as alcoholism, cirrhosis, and hepatitis, the persistence of an approximately threefold excess risk was observed.
CONCLUSIONS: Our findings suggest that patients with diabetes are at increased risk of developing primary liver cancer and perhaps cancers of the biliary tract. The mechanisms involved in the association of diabetes and liver cancer remain to be clarified. Additional studies are needed to determine whether patients with insulin-dependent diabetes mellitus and those with non-insulin-dependent diabetes mellitus differ in their risk for primary liver cancer or whether the risk is affected by the type of diabetes treatment.

Entities:  

Mesh:

Year:  1996        PMID: 8841022     DOI: 10.1093/jnci/88.20.1472

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  93 in total

1.  Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.

Authors:  S Amin; G Mhango; J Lin; A Aronson; J Wisnivesky; P Boffetta; Aimee L Lucas
Journal:  Am J Gastroenterol       Date:  2016-07-19       Impact factor: 10.864

2.  Diabetes therapy and cancer risk: causal effects and other plausible explanations.

Authors:  S Hernández-Díaz; H-O Adami
Journal:  Diabetologia       Date:  2010-02-23       Impact factor: 10.122

Review 3.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

4.  Risk of cancer in a large cohort of U.S. veterans with diabetes.

Authors:  Elizabeth A Atchison; Gloria Gridley; J Daniel Carreon; Michael F Leitzmann; Katherine A McGlynn
Journal:  Int J Cancer       Date:  2011-02-01       Impact factor: 7.396

5.  Loss of FGF21 in diabetic mouse during hepatocellular carcinogenetic transformation.

Authors:  Quan Zhang; Yan Li; Tingting Liang; Xuemian Lu; Xingkai Liu; Chi Zhang; Xin Jiang; Robert C Martin; Mingliang Cheng; Lu Cai
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

6.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.

Authors:  J A Davila; R O Morgan; Y Shaib; K A McGlynn; H B El-Serag
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

7.  Chronic hepatitis C increased the mortality rates of patients with hepatocellular carcinoma and diabetes mellitus in a triple hepatitis virus endemic community.

Authors:  Kuo-Chin Chang; Pei-Shan Tsai; Mei-Chin Hsu; Shu-Fen Hung; Chin-Chen Tsai; Sheng-Nan Lu
Journal:  J Gastroenterol       Date:  2010-01-07       Impact factor: 7.527

8.  Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study.

Authors:  Hsueh-Chou Lai; Shih-Ni Chang; Che-Chen Lin; Ching-Chou Chen; Jen-Wei Chou; Cheng-Yuan Peng; Shih-Wei Lai; Fung-Chang Sung; Yu-Fen Li
Journal:  J Gastroenterol       Date:  2012-10-16       Impact factor: 7.527

Review 9.  Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.

Authors:  Abby B Siegel; Andrew X Zhu
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

10.  Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus.

Authors:  Layla Judi; Ala Toukan; Yousef Khader; Kamel Ajlouni; M Amer Khatib
Journal:  Ann Saudi Med       Date:  2010 Jan-Feb       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.